Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis complete, the long term clinical durability of Feraccru (to be called Accrufer in US), its cost-efficacy and ease-of-use when compared to the standard IV iron, support discussions with potential US partners.
Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive of ongoing discussions
